Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
CAR-T Agreement with University of Pennsylvania
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that it has entered into a Sponsored Research Agreement ("Agreement") with the University of Pennsylvania ("Penn"). The goal of the Agreement is to advance the Chimeric Antigen Receptor ("CAR") T-cells ("HEMO-CAR-T") developed by the Company toward clinical trials. The Agreement is envisaged as the first step of a larger program that aims to achieve clinical proof of concept for HEMO-CAR-T for the treatment of acute myeloid leukemia ("AML").
Dr. Saar Gill, Assistant Professor of Medicine, a hematologist-oncologist physician scientist and Scientific co-Director of the Cell Therapy and Transplantation program at Penn, will serve as Principal Investigator on behalf of Penn. Dr. Gill's laboratory is part of the Center for Cellular Immunotherapies ("CCI"), whose Director, Dr. Carl H. June, conducted pioneering clinical trials of genetically engineered cells including CAR-T cells in patients with HIV and diverse forms of cancer.
Dr. Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: " This is a first and incredibly important step on a direct path to clinical trials for one of our leading product candidates. We are very pleased to be collaborating with the best and first institution that developed CAR-T technology into an approved and globally used treatment for leukemias, which has already saved so many lives. We are confident that this collaboration will dramatically accelerate the development of our CAR-T product candidate, which we believe will have a significant and positive impact in the treatment of acute myeloid leukemia, for which there is currently no real effective treatment."
New investors DYOR
https://www.investegate.co.uk/hemogenyx-pharma-plc--hemo-/rns/car-t-agreement-with-university-of-pennsylvania/202008110700067098V/
And for those that don't open links.New investors DYOR
About AML and CAR-T Therapy
AML, the most common type of acute leukemia in adults, has poor survival rates (a five-year survival rate of less than 30% in adults) and is currently treated using chemotherapy, rather than the potentially more benign and effective form of therapy being developed by Hemogenyx Pharmaceuticals. The successful development of the new therapy for AML would have a major impact on treatment and survival rates for the disease.
CAR-T therapy is a treatment in which a patient's own T-cells, a type of immune cell, are modified to recognize and kill the patient's cancer cells. The procedure involves: isolating T-cells from the patient; modifying the isolated T-cells in a laboratory using a CAR gene construct (which allows the cells to recognize the patient's cancer); amplifying (growing to large numbers) the newly modified cells; and re-introducing the cells back into the patient.
https://www.investegate.co.uk/hemogenyx-pharma-plc--hemo-/rns/car-t-agreement-with-university-of-pennsylvania/202008110700067098V/
About the Center for Cellular Immunotherapies
CCI, under the directorship of Dr. Carl H. June, is focused on coordinated interdisciplinary approaches for the discovery and development of core platform technologies for personalized cell and gene-based therapies in cancer, autoimmune disease, infectious disease, and organ and bone marrow transplantation. CCI interacts with a coalition of investigators in nearly all departments and centers in the Perelman School of Medicine, driving the clinical translation of novel and investigational immune-based therapies. CCI's mission is to accelerate and synergize efforts that quickly transition fundamental immunobiology research into the clinic.
As mentioned above, CCI and the team of Dr. June have conducted numerous clinical trials with CAR T-cells in patients with HIV infection and diverse forms of cancer. The CAR T-cells invented in the June Laboratory were awarded "Breakthrough Therapy" status by the FDA for acute lymphoblastic leukemia ("ALL") in children and adults in 2014 and lymphoma for adults in 2018. This technology has been developed for widespread use by Novartis culminating with the FDA approval of the first CAR T-cell therapy Kymriah ® (tisagenlecleucel) for the treatment of ALL in 2017.
About Dr. Saar Gill and the Gill Laboratory
Saar Gill, MD, PhD, obtained his medical degree from the University of Melbourne in Australia in 1999. He underwent internal medicine training at St Vincent's Hospital in Melbourne, followed by hematology training at the Peter MacCallum Cancer Centre and at the Royal Melbourne Hospital, which he completed in 2008. In 2008 he became a post-doctoral fellow at the laboratory of Robert Negrin at Stanford University, where he studied adoptive cellular therapy with NK cells. In 2011 Dr. Gill moved to the University of Pennsy
New investors DYOR
https://www.investegate.co.uk/hemogenyx-pharma-plc--hemo-/rns/car-t-agreement-with-university-of-pennsylvania/202008110700067098V/